Before the opening bell, eXp World Holdings, Inc. (OTCQB: EXPI), the holding company for The Agent-Owned Cloud Brokerage®, announced its retention of MZ Group as its investor relations advisor. Moving forward, MZ Group will assist and advise EXPI regarding its ongoing communications with shareholders with the aim of strengthening the company’s public brand and broadening its investor base.

“We have chosen to partner with MZ Group to bolster our investor relations and outreach efforts during this time of rapid growth within our Company,” Glenn Sanford, founder, CEO and chairman of EXPI, stated in this morning’s news release. “While we have more than doubled in size over the past year due in large part to the dedicated efforts of our existing agent and broker network, we believe there is room for sustained growth as we continue to invest in our core infrastructure and agent and broker network.”

In recent months, EXPI, through the expansion of subsidiary eXp Realty, has recorded strong growth in terms of both market reach and financial results. As of its latest report, the company’s real estate brokerage division had more than 2,200 real estate professionals spanning 41 states, the District of Columbia and parts of Canada. This marks an increase of nearly 155 percent from the beginning of 2016, when eXp Realty reported just 864 agents.

This market growth has translated into strong financial performance for EXPI in 2016, demonstrating the viability of the company’s current growth strategy. Last month, EXPI released its financial results for the third quarter of 2016, which included a 112 percent year-over-year increase in total revenues to $15.7 million. In the update, the company’s management team attributed this increase to eXp Realty’s growing sales agent base and the resulting rise to sales volume being generated by the real estate brokerage division.

EXPI’s share price has been on a similarly-promising upward trend throughout much of 2016. In January, the company’s PPS hovered around $0.84. By October, EXPI’s common stock climbed to a record high of more than $5.80 following the announcement of a new strategic partnership with Commissions, Inc., a leading provider of web-based real estate marketing and CRM software. The company’s stock is currently trading at around $4.35 per share.

News of EXPI’s retention of MZ Group comes just days after the company’s real estate brokerage division was recognized as a winner of the Oklahoma 2016 Top Workplaces Award by The Oklahoman newspaper. eXp Realty has previously received similar recognition in both Washington, D.C. and Atlanta for its commitment to creating a collaborative, engaging and rewarding work environment.

For more information, visit the company’s website at www.eXpWorldHoldings.com

Let us hear your thoughts: eXp World Holdings, Inc. Message Board

PRO 140, an innovative new therapy for HIV patients developed by Cytodyn Inc. (OTCQB: CYDY), is currently undergoing phase 3 clinical trials, having been administered to several patients, according to a company press release (http://dtn.fm/F40vr). No other details were provided about the initial results of phase 3 trials, but a separate report said actor Charlie Sheen is one of the subjects and that he has achieved undetectable viral load after taking PRO 140.

Sheen, who revealed his HIV status in November last year, has been a part of the study for eight months and is receiving weekly injections of the drug, the report said. The phase 3 study is looking into PRO 140’s safety and effectiveness in HIV patients and is being administered without any other HIV medication to determine whether it alone is enough to fight HIV and help subjects achieve an undetectable viral load.

Cytodyn, a biotech company that focuses on the development of innovative antibody therapies against the human immunodeficiency virus and other diseases, has not officially commented on the Daily Mail report. In a press release this week, however, it announced that several patients have already been treated with PRO 140 as part of the phase 3, multicenter clinical trial which will enroll a total of 300 subjects. All the patients included in the study have CCR5-tropic HIV-1 infection and are clinically stable, being on highly active antiretroviral therapy up to one week after the enrollment.

During the phase 3 trial, the subjects will receive only PRO 140 in the form of subcutaneous injections for 48 weeks to determine whether the product candidate is safe and efficient as a single-agent maintenance therapy for chronic suppression of HIV. PRO 140 is a fully humanized monoclonal antibody that specifically targets the CCR5 entry receptor on CD4 cells, which HIV targets and takes over. The proprietary therapy fights HIV by blocking this entry point and preventing the virus from infecting healthy cells.

CytoDyn CEO and President Nader Pourhassan, Ph.D. said his company expects the monotherapy trial to yield significant results and provide sufficient data to support further clinical and regulatory advancement of the treatment. He explained that the phase 3 trial is nearly a duplicate of the phase 2b trial that ended last year, with an additional objective of determining why some R5 patients are not responding to the therapy as well as others. Out of 15 subjects who continued the trial in the extension arm and received weekly PRO 140 injections in phase 2b trials, 10 maintained an undetectable viral load for more than two years, while four others did not report any changes in their HIV infection. The last patient moved away and could not be monitored.

Pourhassan is confident that the phase 3 trial findings will help determine which patients can achieve long-term HIV suppression and ultimately secure label expansion for PRO 140 as a single agent therapy, given it has low toxicity and virtually no side effects. PRO 140 only targets HIV patients with the R5 strain, Pourhassan added. This strain currently accounts for about 70 percent of HIV infections and 90 percent of newly-diagnosed cases in the United States.

For more information, visit www.cytodyn.com

Moxian, Inc. (NASDAQ: MOXC), a top digital marketing company, uses powerful social media-driven marketing and sales tools to connect online users and merchants. Backed by a flourishing online-to-offline integrated platform, this company offers offline merchants solid opportunities to strengthen their outreach to digital consumers.

Since it was founded in 2013, Moxian has catered to one particular business pain: the merchant’s need to engage with more digitally-savvy consumers. Along the way, this offline-to-online integrated platform operator has expanded from managing its operations from its base in Shenzhen, China, to creating branch offices in Beijing, Malaysia and Hong Kong.

Following the Nasdaq listing of its stock in November 2016 and the official launch of its Moxian+ App in recent months, Moxian is embarking on a new chapter. The company’s Moxian+ mobile application platform connects users to merchant clients through entertaining games, rewards and social events. In return, users provide valuable information that Moxian’s merchant clients can use to successfully market products and services sold at their brick and mortar stores.

From the start, Moxian has designed its products and services to allow merchant clients to run advertising campaigns and promotions targeting potential customers. Its platform was also developed and built to encourage current users to return frequently and to persuade new users to subscribe to its website. Now, Moxian is fully engaged in delivering products and services that compile user data into a comprehensive database, one that allows merchants to study and better understand user behavior and, in turn, improve their dealings with those users.

Over the years, Moxian has also moved beyond focusing on the domestic market in China to the global market as a whole. It has done so by establishing tactical data centers in both China and Singapore. At its data center in China, the company is leveraging the Oracle Exadata Database Machine in a private cloud environment in order to improve database computing, maximize database performance on the cloud platform and further save storage space and cost. And at its data center in Singapore, it is using the Oracle Database Appliance to boost database performance and lower overall investment cost with Flash, memory planning and other smart data technologies.

For more information, visit the company’s website at www.Moxian.com

About NetworkNewsWire

NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, visit https://www.NetworkNewsWire.com

Please see full disclaimers on the NetworkNewsWire website: http://nnw.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.net

According to 4Hoteliers (http://dtn.fm/zOeA9), 85% of travelers across the world are also smartphone users. The article goes on to state that 32% of these travelers use their mobile devices to book travel-related services. The company’s recent webinar, ‘Digital Marketing and Mobile Trends Impacting the Travel Industry’, showed that over 70% of travelers use mobile devices to check their itineraries.

But the increase in mobile usage for travel is not all that is impacting the industry. A more experience-based economy, the new social ecosystem we live in, and the growing preference for recommendations from peers are just some of the digital marketing trends transforming the travel industry, according to Smart Insights (http://dtn.fm/DoC4q). Because travel arrangements are now largely made via the Internet, and the typical consumer is looking for more than just a basic holiday, organizations in the travel industry are having to adapt to a more digital and mobile way of reaching consumers.

During a survey undertaken by Opera Mediaworks (http://dtn.fm/J9gWx), one in three people said that the availability of booking apps would make them more likely to book via mobile, and one in three also said that having research apps available could make them more likely to engage in more travel activities such as eating out, visiting various sights, and more. According to the ‘How People Use Their Phones For Travel’ research published by Google (http://dtn.fm/B5iX2), the top motivating factor for downloading travel apps is to make a specific activity or task easier. Users shared that what they find most valuable about travel apps is the wide range of features and the fact that apps store preferences that make future activities easier.

As a result, NextTrip.com, flagship company of Monaker Group, Inc. (OTCQB: MKGI), designed its own all-in-one travel planner, which gives travelers access to a range of free tools that allow them to import all booking details into one space. The free travel organizer allows users to discover hotels, restaurants, sights, and activities near their points of interest. The all-in-one travel planner helps holidaymakers organize details of their trips, and even split and collect money between groups of people. NextTrip’s travel planner is easy to use, easily accessible, and makes planning a trip while on the move simple thanks to its compatibility with mobile devices.

For more information, visit www.MonakerGroup.com

Let us hear your thoughts: Monaker Group, Inc. Message Board

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company in the business of developing, manufacturing, and globally commercializing products that treat severe burns and wounds. In 2012, MediWound’s innovative drug, NexoBrid™, a burn and wound eschar removal agent, was approved by the European Medicines Agency (EMA) via a centralized procedure. The drug was given orphan indication for removal of dead and damaged skin in adults with burns that are deep partial and full thickness thermal burns.

NexoBrid™ was launched throughout Europe and is now being used in patients with hospitalized burns and wounds. MediWound has initiated phase III clinical trials on NexoBrid™ in the U.S. and pediatric study. The company also has two other products in its pipeline: EscharEx, which is in its phase II study and is for use in patients with chronic wounds, and MWPC003, which is about to enter its phase I study and is for use in patients with connective tissues disorders.

In November of this year, MediWound Ltd. announced third quarter 2016 financial results for the three- and nine-month periods ended September 30, 2016. The company reported revenue for the quarter of $518,000, compared to just over $100,000 for the same quarter of 2015. This was put down to the growing sales of NexoBrid™. The nine-month period results showed total revenue of $1.1 million, compared to $0.3 million for the same nine-month period of the previous year. MDWD will be spending the remainder of 2016 investing primarily in sales and marketing activities relating to the further adoption of NexoBrid™ in Europe.

Aegis Capital Corp. (http://dtn.fm/l63Bn) initiated coverage on MediWound Ltd., giving the company a ‘Buy’ rating with a price target of $11 per share. This rating was given based on the fact that the company has made significant progress in the area of wound debridement. According to the report, MDWD’s NexoBrid™ is showing significantly faster, more selective, safer, and more cost efficient results compared to current treatments. The report also highlights the possibility for the company to integrate into the chronic wound care market with EscharEx and markets relating to connective tissue disorders with its pipeline product MWPC003.

Despite Zacks Investment Research lowering the company’s status from a ‘Buy’ rating to a ‘Hold’ rating, six other research analysts have given MDWD a ‘Buy’ rating, and Wells Fargo & Co. offered MediWound an ‘Outperform’ rating with a price target on the stock of $14. The company has a consensus ‘Buy’ rating with a consensus price target of $13.25, all according to Cerbat Gem Market News and Analysis (http://dtn.fm/Ch85p).

Institutional investors and hedge funds are now said to own over 27% of MediWound shares, after Migdal Insurance & Finance Holdings, Wells Fargo & Company MN, and Oppenheimer & Co. bought new positions in the company’s stock. Wellington Management Group LLP and United Services Automobile Association also increased their positions in MediWound. As of this writing, the company has a market cap of $107.17 million, with an enterprise value at $84.15 million, and shares currently selling at around $4.90 per share.

For more information, visit the company’s website at www.mediwound.com

As an eventful year for Globus Medical, Inc. (NYSE: GMED) is nearing an end, the leading medical device company experienced a substantial surge in trading volume on December 06. Equities.com (http://dtn.fm/Rab1C) noted a 1.3% gain of Globus Medical, Inc. Class A stock, closing at $23.31. The stock, which averages a daily volume of 1.11 million shares over the last month, captured the attention of numerous institutional investors and analysts when a surge of 11.57 million shares traded hands on 28,116 trades. The article states, “Generally speaking, when a stock experiences a sudden spike in trading volume, it may be seen as a bullish signal for investors. An increase in volume means more market awareness for the company, potentially setting up a more meaningful move in stock price.”

Increased awareness has been building for the medical device company during 2016, including the unveiling of its investigational robotics system Excelsius at the 2016 North American Spine Society (NASS) meeting held in late October. Per articles from MassDevice.com (http://dtn.fm/Of7Fc), and Becker’s Spine Review (http://dtn.fm/9t2Mm), Globus Medical expressed its anticipation of an approval and launch of the platform in early to mid-2017 to investment bank Leerink Partners. The MassDevice.com article also states that Leerink spoke with surgeons who were very interested in a trial of the platform as it becomes available. This adds credence to the company’s position as one of the “three main players” in the burgeoning surgical robotics industry (http://dtn.fm/u9oeH), citing recent commentary from the Medical Device and Diagnostic Industry website. MDDI mentions that surgical robots are only used in roughly 5% of spine procedures today, but that a survey by RBC Capital Markets indicates the potential for rapid adoption growth.

This potential for mass adoption has also been noted by financial analysis firm, Aegis Capital (http://dtn.fm/s1Rhi), in a report from November 30th that preceded Tuesday’s surge in trading activity. The firm set a $31 target price that was achieved, in part, by Globus Medical’s promising pipeline of emerging technologies, namely the robotics platform and trauma. The report calls attention to the system’s ability to serve as a competitor to Medtronic’s O-Arm with Stealth Station navigation. Those systems, which do not include robotic assistance, retail for more than $1 million, placing Globus Medical in a position to charge a premium on its own systems, as they incorporate full feature navigation. As a result, the company believes the customers of the roughly 900 O-Arms installed worldwide to be prospective customers and early adopters. Globus Medical intends to demonstrate, through clinical studies, the system’s time and money-saving benefits, as well as the added layer of predictability and accuracy it affords.

Headquartered in Audubon, Pennsylvania, Globus Medical, Inc. is a leading musculoskeletal implant manufacturer with the singular focus of advancing spinal surgery through the development of innovative engineering and technology. To date, Globus Medical has developed and released more than 150 spine products.

For additional information, visit www.GlobusMedical.com

Intellipharmaceutics International, Inc. (NASDAQ: IPCI) is a pharmaceutical company in the business of researching, developing, and manufacturing new and generic controlled and targeted release oral solid dosage drugs. The company has a large product portfolio which all follow a New Drug Application (NDA) 505(b)(2) U.S. Food and Drug Administration (FDA) regulatory pathway. The company’s controlled-release generic products follow an Abbreviated New Drug Application (ANDA) pathway.

IPCI currently has 11 products in the pipeline, more than half of which have either been filed for FDA approval or have already been approved. Two products, Regabatin™ XR and Carvedilol, are still in clinical trial stages. The company utilizes its patented Hypermatrix™ technology as a drug delivery platform that can be used to efficiently develop an array of new and existing pharmaceuticals. IPCI’s portfolio covers therapeutics areas such as pain, neurology, cardiovascular, diabetes, and gastrointestinal tract.

In October of this year, Intellipharmaceutics International released its financial results for the fiscal quarter ended August 31, 2016. During the quarter, IPCI reported revenues of $600,000 relating to its license and commercialization agreement with Par Pharmaceuticals, Inc. At this time, the company also announced the tentative approval by the FDA of its generic Seroquel XR®. Additionally, IPCI announced that it had signed an exclusive license and commercial supply agreement with Mallinckrodt, LLC for its generic Lamictal® XR™, Seroquel® and Pristiq®.

Between May 31, 2016 and August 31, 2016, the company reported an increase in cash of $1.8 million. Intellipharmaceutics International, Inc. reported a cash balance of $4.5 million after the $3 million payment from Mallinckrodt. As a result of this recent activity, Aegis Capital Corp. (http://dtn.fm/zD6vt) offered a company update, giving IPCI a ‘Buy’ rating with a price target of $8 per share. The update was released after the company submitted an NDA for abuse-deterrent Rexista extended release tablets. In addition, Intellipharmaceutics International has developed a system to pair with Rexista in order to deter opioid abuse, which has been declared as an epidemic by the CDC.

According to the Cerbat Gem Market News and Analysis (http://dtn.fm/D3r4V), other equities research analysts, such as Maxim Group and Brean Capital, also gave the company a ‘Buy’ rating with price targets of $6 and $8 per share, respectively. Institutional investor Morgan Stanley raised its position in the company by over 4%, giving it just below 62,000 shares of IPCI worth $130,000. Hedge funds and institutional investors now own 1.68% of Intellipharmaceutics International, Inc., and the company’s market cap currently stands at $84.29 million.

For more information, visit the company’s website at www.intellipharmaceutics.com

Revance Therapeutics, Inc. (NASDAQ: RVNC), a biotechnology company focused on the development, commercialization, and manufacture of botulinum toxin products for use in aesthetic and therapeutic indications, including dermatology and neurology, recently announced its operating results for the third quarter of 2016 ended September 30.

A summary of the company’s financial results highlighted research and development expenses of $10.3 million for the three-month period, $2.7 million less than in the same quarter of 2015. The decrease in expenses was largely attributable to a reduction in clinical trial activities. Research and development costs for the nine-month period were up $5.3 million.

The increase in overall expenses for the company came from an increase in personnel costs and manufacturing activities. In addition, the company recently acquired the necessary patents for botulinum toxin and put forward patent applications for Botulinum Toxin Research Associates, Inc. (BTRX).

On November 29, Aegis Capital Corp. (http://dtn.fm/b4cKx) initiated coverage on Revance Therapeutics, Inc., giving the company a ‘Buy’ rating with a price target of $28 per share. Aegis gave the ‘Buy’ rating based on the company’s opportunity to tap into the $3 billion botulinum toxin market, which is expected to reach $5.6 billion by 2020.

With Botox currently holding approximately 85% of the market share, Aegis reported that RT002, RVNC’s drug candidate for the treatment of moderate to severe glabellar lines in adults, will likely stand out from competitors in the market. This has been put down to the fact that, unlike other drugs, RT002 targets specific areas, effectively limiting its spread to other regions.

Aegis expects RT002 to gain a market share of approximately 21% by 2025, as long as phase III trials prove to be as positive as the company’s phase II BELMONT study. RT002 is also currently being evaluated as a potential treatment for plantar fasciitis, a condition for which corticosteroids are the first method of treatment. As a result, the drug could also be the first of its kind to gain FDA approval for this indication.

Other analysts have also taken an interest in Revance. According to Cerbat Gem Market News and Analysis (http://dtn.fm/GR6xu), “two research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock.”

Reiterating the optimism regarding Revance’s forward growth potential, a number of large investors have recently increased their stakes in the company. BlackRock Group Ltd., BlackRock Advisors LLC, FineMark National Bank & Trust, and American International Group, Inc. all raised their positions in Revance during the second and third quarters of this year by 4.3%, 15.8%, 750% and 10.9%, respectively. At close of market yesterday, the stock was selling at $16.80 per share.

For more information, visit the company’s website at www.revance.com

Now that residents of the Golden State have approved Proposition 64, California joins the District of Columbia and the states of Alaska, Colorado, Maine, Massachusetts, Nevada, Oregon, and Washington in legalizing the recreational use of marijuana for adults. Together, these eight states and the U.S. capital generate about one-quarter of U.S. gross domestic product (GDP). If they were one nation-state, that entity would rank as the world’s third largest economy.

Based in one of those states, Nevada, Singlepoint, Inc. (OTC: SING) is poised to profit from these promising presentiments. It recently revived its SingleSeed subsidiary, which several years ago began offering payment-processing services to dispensaries in Colorado and Washington State. The company intends on leveraging these footholds to be a “first mover” in the market.

These nine jurisdictions may have enough economic clout to make the Feds allow banks to open accounts for marijuana businesses, and California is already testing that proposition. A report in the LA Times (http://dtn.fm/lSB6a) last Friday revealed that California State Treasurer John Chiang had ‘appointed a working group to figure out how to address problems caused by the unwillingness of federally regulated banks to handle money from pot businesses’. Mr. Chiang also wrote the President-elect, Donald Trump, seeking guidance on the issue.

The root of the problem is that, by federal law, cannabis remains a Schedule I substance under the Controlled Substances Act of 1970. Accordingly, “even transporting or transmitting funds known to have been derived from the distribution of marijuana is illegal”, said the Federal Reserve Bank of Kansas City in a recent court case. The suit in that case, brought to compel the Fed to approve a ‘master account’ for the first credit union for marijuana in Colorado, was dismissed by the court. The judge said that unlike federal prosecutors, who might not enforce the law if financial institutions observed certain guidelines for dealing with the marijuana industry, a court could not ‘look the other way’.

The guidelines referred to were issued in February 2014 by the Financial Crimes Enforcement Network (FinCEN) of the U.S. Treasury Department. They offered financial institutions clarification on how they could provide services to marijuana-related businesses consistent with their Bank Secrecy Act obligations and were designed to ensure that marijuana was kept out of the hands of minors, that marijuana businesses were not operated by or associated with criminal enterprises, and that the industry did not exacerbate gun violence nor adversely affect public health.

Since these guidelines were published, a number of community banks and credit unions have sought to offer services to marijuana outfits, but the larger national banks have kept their distance. The lawsuit referred to above was filed by Colorado chartered Fourth Corner Credit Union in Denver after the Federal Reserve Bank of Kansas City turned down its application for a ‘master account’, an account a financial institution holds at one of the reserve banks.

Cases like this one show the barriers standing in the way of legitimate marijuana establishments. As Treasurer Chiang’s letter to the President-elect points out:

“This conflict between federal and state rules creates a number of problems for the states that have legalized cannabis use, including difficulties collecting tax revenue, increased risk of serious crime, and the inability of a newly legal industry under state law to effectively engage in banking and commerce.”

Of course, it is Congress that will have the final say. It seems impossible for this impasse to be resolved unless cannabis is de-scheduled. For marijuana shops, for banks and for Singlepoint, Inc., the day that happens will be a bank holiday.

For more information, visit the company’s website at www.Singlepoint.com

Let us hear your thoughts: Singlepoint, Inc. Message Board

The Trade Desk, Inc. (NASDAQ: TTD) is a technology company that allows buyers to use proprietary data to better target their advertising dollars. With The Trade Desk platform, organizations are able to use fully automated and programmatic means to buy advertising space on a range of media where specific consumers are more likely to use their products or services. Organizations are able to create, manage, and optimize digital advertising campaigns in formats such as display, video, audio, and more.

Headquartered in Ventura, California, with other offices in the U.S, Europe, and Asia, TTD offers an integrated feature set to its customers that includes omnichannel targeting, data management that gives insight into audiences, enterprise APIS, and HD reporting. The company runs through a self-service, cloud-based platform, offering services across a multitude of devices, including mobile devices, computers, and television.

Most recently, The Trade Desk, Inc. was ranked number 55 on the Deloitte’s 2016 Technology Fast 500™ (http://dtn.fm/ai7PI) list of the fastest growing media, telecommunications, technology, energy, and life science companies in North America. The ranking for both private and public companies is based on the percentage of fiscal year growth between 2012 and 2015. TTD grew by over 1,800% during that period.

Earlier in November, The Trade Desk reported its financial results for the third quarter of 2016 (http://dtn.fm/UNu7p). Since becoming a public company in September, the company reported an increase of over 80% in revenue. Revenue for the third quarter came in at $53 million, compared to $28.8 million during the third quarter of 2015.

Highlights of the report included the fact that TTD’s customer retention rate was over 95% for the quarter, and the company is expanding with new offices expected in Orange County, California, and Hong Kong, alongside plans to open new offices in both Europe and Asia Pacific. The company is aiming to report revenues of up to $62 million for the fourth quarter of 2016 and an adjusted EBITDA margin of 30%.

According to Cerbat Gem Market News and Analysis (http://dtn.fm/Shg8w), The Trade Desk’s report of $0.24 earnings per share for the quarter was higher than Thomson Reuters’ consensus estimate by $0.03. Equities research analysts have made predictions of $0.85 EPS for the company for the current fiscal year.

Jefferies Group and Cantor Fitzgerald gave The Trade Desk a ‘Buy’ rating with target prices on the stock of $35 and $30, respectively. The company received a consensus ‘Buy’ rating with an average price target of $33.13.

For more information, visit the company’s website at www.thetradedesk.com